Exercise Training in Grown-up Congenital Heart Disease

NCT ID: NCT02825472

Last Updated: 2016-07-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-02-29

Study Completion Date

2017-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Rationale: Regular physical activity and aerobic exercise training are related to decreased cardiovascular mortality in healthy individuals, as well as in individuals with cardiovascular risk factors and cardiac patients. Unfortunately, no such data is available on exercise training in adult patients with congenital heart disease.

Objective: The objective of the ExTra GUCH trial is to assess whether encouragement of a six-month sports participation program in addition to usual care in symptomatic adult patients with congenital heart disease improves exercise capacity and quality of life, and lowers serum N-terminal prohormone brain natriuretic peptide (NT-proBNP) levels.

Study design: International, multi-centre parallel randomized controlled trial.

Study population: Adult patients with congenital heart disease, who are in New York Heart Association (NYHA) class II or III.

Intervention (if applicable): The intervention group receives a six-month individualized exercise training program, the control group receives usual care.

Main study parameters/endpoints: The primary outcome is the change in peakVO2 between patients in the sports participation group, and the control group. Secondary outcome measures are change in NYHA functional class, quality of life, and NT-proBNP levels. The primary safety outcome is the composite of all hospitalizations, and all deaths during, or within three hours after exercise. The secondary safety outcome is the composite of all exercise related injuries for which medical attention is sought.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators intend to submit the trial design of this study for this purpose.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Congenital Heart Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Exercise training program

Six-months sports participation, three times per week for 30 minutes in the target heart rate zone

Group Type ACTIVE_COMPARATOR

exercise training

Intervention Type BEHAVIORAL

3 times per week 30 minutes of exercise training in the target heart rate zone

No exercise training program

no exercise training program, usual care

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

exercise training

3 times per week 30 minutes of exercise training in the target heart rate zone

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years
* Congenital heart disease of all complexities
* NYHA Class II or III

Exclusion Criteria

* Inability to give informed consent
* Inability to participate in an exercise training program
* Exercise-induced arrhythmia and/or ischemia
* Cyanosis at rest
* Pregnancy
* Major cardiovascular event and/or procedure within three months previous to inclusion.
* Participation in interventional clinical trial
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Berto J Bouma

MD, PhD

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Barbara Mulder, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

AIDS Malignancy Consortium

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Cardiology, I.R.C.C.S. Policlinico San Donato Milanese

Milan, Piazza Edmondo Malan, Italy

Site Status NOT_YET_RECRUITING

Hospital

Amsterdam, North Holland, Netherlands

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Italy Netherlands

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Berto Bouma, MD, PhD

Role: CONTACT

0031205669111

Michiel Winter, MD, PhD

Role: CONTACT

0031205669111

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Massimo Chessa, MD, PhD

Role: primary

0039252774531

Berto Bouma, MD, PhD

Role: primary

0031205669111

Michiel Winter, MD, PhD

Role: backup

0031205669111

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NL5378201815

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.